EyePoint Secures Two US Patents for DEXYCU

April 13, 2018: By Jon Swedien

EyePoint Pharmaceuticals

The US Patent and Trademark Office (USPTO) issued EyePoint Pharmaceuticals a notice of allowance for two patents covering DEXYCU, the Watertown, Massachusetts-based company (formerly pSivida) announced April 12.

DEXYCU (dexamethasone intraocular suspension) is FDA-approved for the treatment of postoperative inflammation associated with cataract surgery.

The first patent includes claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small (4-6µL) amounts of dexamethasone in triethyl acetyl citrate, EyePoint said. Once issued, the patent will expire in 2034, the company said.

The second patent includes claims relating to loading and delivering a small dose volume from an injection syringe. Once issued, it will expire in 2032.

After issuing a notice of allowance, the USPTO requires applicants to pay fees before it issues patents.

DEXYCU delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating a patient’s need to take medicated eye drops several times a day for several weeks on a titrated schedule, EyePoint said.

DEXYCU employs the firm’s Verisome technology to dispense a biodegradable extended-release formulation of dexamethasone into the anterior chamber of the eye, EyePoint said.

EyePoint was formed after pSivida Corp acquired privately held Icon Bioscience of Newark, California, in March and rebranded.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023